1
- --------------------------------------------------------------------------------
Registration No. 333-
- ---------------------------------------------------------------------------------------------------------------------------------------------------------------
As filed with the Securities and Exchange Commission on July 14, 1999March 2, 2000
DRAFT 2/28/00
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
-------------------------
FORM S-3
Registration Statement
Under The
Securities Act of 1933
------------------------
INTERNATIONAL ISOTOPES INC.
(Name of Small Business Issuer in its Charter)
TEXAS 2835 74-276837
(State or other Jurisdiction (Primary Standard Industrial (I.R.S. Employer
of Incorporation or Organization) Classification Code Number) Identification No.)
3100 JIM CHRISTAL2835
(Primary Standard Industrial
Classification Code Number)
1500 SPENCER ROAD
Denton, Texas 76207-9987DENTON, TEXAS 76205
(940) 484-9492323-2610
(Address and Telephone Number of Principal Executive Offices
and Principal Place of Business)
IRA LON MORGAN, CHAIRMAN
3100 JIM CHRISTALDAVID M. CAMP
1500 SPENCER ROAD
Denton, Texas 76207-9987DENTON, TEXAS 76205
(940) 484-9492323-2610
(Name, Address and Telephone Number of Agent for Service)
COPY TO:
CURTIS R. ASHMOS
LOCKE LIDDELL & SAPP LLP
100 CONGRESS, SUITE 300
AUSTIN, TEXAS 78701
(512) 305-4716
APPROXIMATE DATE OF PROPOSED SALE TO THE PUBLIC:
From time to time after this Registration Statement becomes effective.
If the only securities being registered on this form are being offered
pursuant to dividend or interest reinvestment plans, check the following
box. [ ]
If any of the securities being registered on this form are to be
offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box. [X]
If this form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. [ ]
If this form is a post-effective amendment filed pursuant to Rule
462(c) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration
statement for the same offering. [ ]
If delivery of the prospectus is expected to be made pursuant to Rule
434, please check the following box. [ ]
TITLE OF EACH CLASS- -------------------------------------------------------------------------------------------------------------
PROPOSED MAXIMUM PROPOSED MAXIMUM
TITLE OF SECURITIES TO BEEACH CLASS AMOUNT TO BE OFFERING PRICE PER AGGREGATE OFFERING AMOUNT OF
REGISTEREDOF SECURITIES TO BE REGISTERED SHARE PRICE REGISTRATION FEE
REGISTERED
- ------------------- ---------------- ------------------ ------------------ -----------------------------------------------------------------------------------------------------------------------------
Common Stock, $.01 1,616,978 shares $6.75(1) $10,914,601(1) $2,881.45
par value
3,911,710 shares $9.03125(1) $35,327,631(1) $ 9,821.08- -------------------------------------------------------------------------------------------------------------
(1) Estimated in accordance with Rule 457(c) of the Securities Act of
1933 solely for the purpose of calculating the registration fee based upon an
assumed price of $9.03125,$6.75, the average of the high and low sales prices of the
Common Stock as reported on Nasdaq SmallCap Market on July 12, 1999.February 28, 2000.
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE
OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT
SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION
STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF
THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME
EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(a),
MAY DETERMINE.
2
PROSPECTUS
3,911,7101,616,978 SHARES
INTERNATIONAL ISOTOPES INC.
COMMON STOCK
-------------------------
This Prospectus relates to the offering for resale of 3,911,7101,616,978 shares
of Common Stock, par value $.01 per share (the "Common Stock"), of International
Isotopes Inc. ("I3"I(3)" or the "Company"). All of the Common Stock being
registered may be offered and sold from time to time by certain selling
stockholders of the Company. See "Selling Stockholders" and "Manner of
Offering." The Company will not receive any proceeds from the sale of the Common
Stock by the Selling Stockholders.
The Company's Common Stock is quoted on the Nasdaq SmallCap Market
under the symbol "INIS" and is listed on the Boston Stock Exchange ("BSE") under
the symbol "ITL." On July 12, 1999,February 28, 2000, the last reported sale price for the
Company's Common Stock on the Nasdaq SmallCap Market was $ 9.1875$6.875 per share.
-----------------------------------
THE SECURITIES OFFERED HEREBY INVOLVE A HIGH DEGREE OF RISK.
SEE "RISK FACTORS" ON PAGE 1.
-----------------------------------
NEITHER THE SECURITIES AND EXCHANGE
COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED
OR DISAPPROVED THESE SECURITIES OR DETERMINED IF THIS
PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE
CONTRARY IS A CRIMINAL OFFENSE.
-----------------------------------
The Company has not authorized any person, agent or entity to give any
information or make any representation other than those contained in this
Prospectus (including material incorporated by reference herein). You should not
rely on any such information or representation as having been authorized by the
Company. This Prospectus is not an offer to sell the securities and it is not
soliciting an offer to buy the securities in any state where offers or sales are
not permitted.
The date of this Prospectus is July 14, 1999March , 2000
3
TABLE OF CONTENTS
Forward Looking Statements .............................................................................................. 1
The Company.................................................................Company .............................................................. 1
Risk Factors................................................................Factors ............................................................. 1
Selling Stockholders ............................................................................................................ 2
MannerPlan of Offering ......................................................... 6Distribution ..................................................... 4
Incorporation of Certain Documents by Reference ............................ 7.......................... 4
Legal Matters .............................................................. 8............................................................ 6
Experts .................................................................... 8.................................................................. 6
Available Information....................................................... 8Information .................................................... 6
4
FORWARD-LOOKING STATEMENTS
This Prospectus contains, or incorporates by reference, certain
statements that may be deemed "forward-looking statements" within the meaning of
Section 27A of the Securities Act and Section 21E of the Exchange Act. All
statements, other than statements of historical facts, that address activities,
events or developments that the Company intends, expects, projects, believes or
anticipates will or may occur in the future are forward-looking statements. Such
statements are based on experience, market trends, our perception of historical
trends, current conditions, expected future developments and other factors
believed to be appropriate. The forward-looking statements included in this
Prospectus are also subject to a number of material risks and uncertainties,
including but not limited to economic, competitive, market, governmental and
technological factors affecting the Company's operations, production, markets,
products, services and prices, and other factors discussed in our filings under
the Securities Act and the Exchange Act. Investors are cautioned that such
forward-looking statements are not guarantees of our future performance and that
actual results, developments and business decisions may differ from those
envisioned by our forward-looking statements.
THE COMPANY
International Isotopes Inc., a Texas corporation (the "Company," "We"
or "I(1/4)"I(3)" ), is a developmental stage Company that has begun executing plans for
operations in the production, marketing, and distribution of a full range of
products used in diagnostic and therapeutic nuclear medicine, research and
industry. Completion of the plans we have developed will establish the first
independent commercial domestic producer of a full range of finished
radiopharmaceuticals (on a contract or joint venture basis), pharmaceutical
grade radioisotopes, radioisotopes and medical devices for commercial sale to
the nuclear medicine industry for the diagnosis and therapeutic treatment of
cancer and other diseases. We are also engineering instrumentation and products
for the radiation therapy and medical imaging markets.
Our principal executive offices are located at 3100 Jim Christal1500 Spencer Road,
Denton, Texas 76207-9987.76205. The telephone number is (940) 484-9492.323-2610.
RISK FACTORS
An investment in our Common Stock is speculative and involves a
substantial degree of risk. Investors should carefully consider, along with
other information in this Prospectus, the considerations and risks set forth in
the Company's Annual Report on Form 10-K for the year ended December 31, 19981999
and other reports and documents filed by the Company from time to time with the
SEC in evaluating an investment in our Company. You should not purchase any
Common Stock unless you can afford to lose your entire investment.
5
SELLING STOCKHOLDERS
The following table sets forth certain information, as of June 30, 1999,February 29, 2000 with
respect to the shares of Common Stock beneficially owned prior to the offering
and the shares being offered hereby by the stockholders listed below (the
"Selling Stockholders"). All of the shares of Common Stock offered hereby were
issued originally, or underly other securities issued originally in transactionsa transaction not
involving a public offering. Absent the current registration, such shares may
not be sold by the Selling Stockholders, except in certain limited situations
including compliance with Rule 144 under the Securities Act.
The shares wereSelling Stockholders on February 1, 2000 acquired as follows:
o 1,062,741 shares were issued in May and June 1999 to a total of
36 accredited investors pursuant to a private
placement of Units
(the "1999 Private Placement"), each Unit consisting of one share1,054,652 shares of the Company's Common Stock at $9.10 per share, plus a three
year Warrantand Warrants to
purchase up to an additional share527,326 shares of the Company's Common Stock. The
shares offered hereby represent the shares of Common Stock at
$10.00 per share.
o 1,062,741issued to the Selling
Stockholders in the private placement and the shares are reserved for issuanceof Common Stock issuable
upon exercise of the Warrants issued in connection withWarrants. In addition, the 1999 Private Placement.
o 814,680Company is registering 35,000
shares are reserved for issuance upon exercise of certain
Warrants issuedCommon Stock that were given to accredited investors who had participated inDavid M. Camp, the Company's 1998 Private Placement.
o 114,680 shares were issued in connection with the Company's 1998
Private Placement.
o 98,039 shares were issued to Endotech, Inc. in paymentnewly
hired President and CEO, as part of royalties pursuant to a license agreement related to the
Company's I-125 brachytherapy seeds.
o 758,829 additional shares are being registered on behalf of the
Company's Chairman. These shares represent his original founders
shares.initial employment package.
SHARES OF COMMON STOCK
BENEFICIALLY OWNED PRIOR SHARES OFFERED BY THIS PERCENTAGE OWNED FOLLOWING
NAME PRIOR TO THIS OFFERING BY THIS PROSPECTUS(2)PROSPECTUS OFFERING(1)
---- ---------------------- ------------------------------------- ---------- ------------
Ira Lon Morgan* 1,853,935 1,341,935
Tommy Thompson* 223,625 24,000
Virgil Simmons* 257,429 12,000
William W. Nicholson * (3) 982,589 36,000
Lighthouse Investment Fund, LP 81,825 81,825 0%
Pharos Fund Limited 531,810 531,810 0%
Lighthouse Partners USA, LP 204,540 204,540 0%
Gryphon Partners, L.P. 122,850 122,850 0%
Archer Fund, L.P. 13,650 13,650 0%
Montrose Investments L.P. 109,092 109,092 0%
Duck Partners, L.P. 68,181 68,181 0%
Hull Overseas, Ltd. 68,181 68,181 0%
Stanford C. Finney, Jr 54,546 54,546 0%
Rainbow Trading Corporation 49,092 49,092 0%
Rainbow Trading Venture Partners 27,273 27,273 0%
Paul Restaino 13,638 13,638 0%
Daurice White cust for 145,000 15,000 (2)
Daniel Patrick McCormack UGMA/TX
Daurice White cust for 145,000 15,000 (2)
-2-
6
SHARES OF COMMON STOCK
BENEFICIALLY OWNED PRIOR SHARES OFFERED BY THIS PERCENTAGE OWNED FOLLOWING
NAME PRIOR TO THIS OFFERING BY THIS PROSPECTUS(2)PROSPECTUS OFFERING (1)
---- ---------------------- ------------------------------------- ---------- ------------
Auric Partners 704,428 595,428
Endotech, Inc. 127,056 98,039
Three Eyes Partners, Ltd. 44,000(1) 12,000
John Paul Dejoria 110,000 30,000
Richard Dusansky 35,000(1) 19,000
Interfin Corporation 187,000 91,000
Granite Capital, L.P. 380,130 257,490
Granite Capital II, L.P. 14,250(1) 14,250
Granite Capital Overseas Limited 41,800(1) 41,800
Granum Value Fund 53,600(1) 53,600
Daniel Patrick McCormack 166,000 34,000
John William McCormack 166,000 34,000
MeganUGMA/TX
Daurice White cust for 145,000 15,000 (2)
Meagan Anne McCormack 166,000 34,000
Elkhorn Partners Limited Partnership 18,800(1) 12,400
James and Marie Keane 124,000 12,000
James B. Skaggs 22,000(1) 6,000
Morgan Keegan Custodian FBO James B.
Skaggs IRA 22,000 6,000
TheUGMA/TX
Nicholas Leone 15,000 15,000 0%
Edward O. Throp 52,500 52,500 (2)
Belfer Family Irrevocable Trust 66,000(1) 18,000Investments, LP 67,500 67,500 (2)
Interfin Corporation 144,800 27,300 (2)
Carr Investments, Ltd. 30,000 30,000 0%
David M. Camp 235,000 35,000 (2)
-3-
7
SHARES OF COMMON STOCK
BENEFICIALLY OWNED SHARES OFFERED
NAME PRIOR TO THIS OFFERING BY THIS PROSPECTUS(2)
---- ---------------------- ---------------------
Parsow Partnership, Ltd. 33,200(1) 23,600
Patrick Mackin 64,000(1) 32,000
Peter Schwalje 21,000(1) 13,000
T&LRM Family Partnership, Ltd. 54,988(1) 22,988
Gary Schwendiman (4) 207,000 6,000
Schwendiman Consulting Group
Retirement Plan 11,000(1) 3,000
Schwendiman Global Health Sciences
Fund, L.P. 64,000(1) 18,000
Biotechnology Fund, L.P. 110,000 30,000
Robert Dee Schwendiman 10,988(1) 10,988
Robert Dee Schwendiman 34,904(1) 34,904
John Luther King and Teresa Carter King 165,000 101,000
LKCM Investment Partnership 286,000 190,000
Fred Smithline 160,000 12,000
Stephen A. Kaplan 44,000(1) 12,000
Thomas R. Schoonover 70,000(1) 54,000
Thomas Schoonover, Trustee 44,500(1) 44,500
-4-
8
SHARES OF COMMON STOCK
BENEFICIALLY OWNED SHARES OFFERED
NAME PRIOR TO THIS OFFERING BY THIS PROSPECTUS(2)
---- ---------------------- ---------------------
George F. Schoonover 7,000(1) 7,000
Bette H. Schoonover 7,000(1) 7,000
Jack Gourley, Jr. 3,500(1) 3,500
Thomas N. and Patricia S. Jones 3,500(1) 3,500
Thomas N. Jones, Trustee, Thomas
Jones M/P/P/S Plan 3,500(1) 3,500
John Baccich 14,000(1) 14,000
Theresa Rains 3,500(1) 3,500
James K. and Moni C. Eichelberger 267,340 87,956
Moni C. Eichelberger 61,388(1) 44,000
Lori K. Eichelberger Trust, Moni C.
Eichelberger, Trustee 79,440(1) 54,988
Jeffrey K. Eichelberger Trust,
Moni C. Eichelberger, Trustee 81,540(1) 54,988
Jeffrey Eichelberger 3,300(1) 3,300
John H. Curttright and Pamela P.
Curttright 1,100(1) 1,100
Renee Belfer Trust,
Robert A. Belfer, Trustee 43,956(1) 43,956
Double I Investors 88,000(1) 24,000
-5-
9
SHARES OF COMMON STOCK
BENEFICIALLY OWNED SHARES OFFERED
NAME PRIOR TO THIS OFFERING BY THIS PROSPECTUS(2)
---- ---------------------- ---------------------
Double I Group 55,000(1) 55,000
John Bryan King 22,000(1) 22,000
Scott C. Hollman 22,000(1) 22,000
Brent Clum 10,000(1) 10,000
David Dowler 10,000(1) 10,000
John Bryan King and Mason King 11,000(1) 11,000
Lee Halford, Jr. 6,000(1) 6,000
Jeff Alexander and Laura Alexander 5,500(1) 5,500
Scott and Julie Kleberg Investment
Partnership, L.P. 11,000(1) 11,000
Ralph D. McBride 44,000(1) 12,000
* Director or Officer/Director- -------------------------------------------------------------------------------
Insert list of the Companynames and shares offered
(1) Less than 1% of Common Stock outstanding
(2) Assumes all shares of Common Stock offered hereby are sold in this
offering. There is no assurance that the Selling Stockholders will sell
any or all of the shares of Common Stock offered hereby.
(3)(2) Less than 1% of total shares outstanding.
-3-
7
PLAN OF DISTRIBUTION
The shares beneficially owned includes 133,000 shares beneficially owned by
Auric Partners, of which Mr. NicholsonCompany is a partner.
(4) Beneficially owned amount includes 11,000 shares beneficially owned by
Schwendiman Consulting, 64,000 shares beneficially owned by Schwendiman
Global Health Sciences, and 110,000 shares beneficially owned by
Biotechnology Fund, L.P.
-6-
10
MANNER OF OFFERING
The shares ofregistering the Common Stock ("Registrable Securities")
on behalf of the Selling Stockholders ("Holders"). As used herein, the term
Holder means the holder of the Registrable Securities and includes donees and
pledgees selling Registrable Securities received from a named Holder after the
date of this Prospectus. All costs, expenses and fees in connection with the
registration of the Registrable Securities offered hereby will be borne by the
Company. Brokerage commissions and similar selling expenses, if any,
attributable to the sale of Registrable Securities will be borne by the Holders.
Sales of Registrable Securities may be soldeffected by Holders from time to time by
the Selling Stockholders,in
one or by pledgees, donees, transferees or other
successors in interest. Such salesmore types of transactions (which may be made in theinclude block transactions) on
Nasdaq, SmallCap Market, on the Boston Stock Exchange orBSE, in the over-the-counter market, in negotiated transactions,
through put or otherwise,call options transactions relating to the Registrable Securities,
through short sales of Registrable Securities, or a combination of such methods
of sale, at market prices andprevailing at terms then prevailingthe time of sale, or at prices related tonegotiated
prices. Such transactions may or may not involve brokers or dealers. The Holders
have advised the then current
market price,Company that they have not entered into any agreements,
understandings or arrangements with any underwriters or broker-dealers regarding
the sale of their securities, nor is there an underwriter or coordinated broker
acting in negotiated transactions. The shares of Common Stock may be
sold in one or more of the following: (a) a block trade in which the
broker-dealer so engaged will attempt to sell the shares as agent but may
position and resell a portion of the block as principal to facilitate the
transaction; (b) purchases by a broker-dealer as principal and resale by such
broker-dealer for its account pursuant to this Prospectus; (c) an exchange
distribution in accordanceconnection with the rulesproposed sale of such exchange; and (d) ordinary
brokerage transactions and transactions in which the broker solicits purchasers.
In affecting sales, broker-dealers engagedRegistrable Securities by the
Selling Stockholders may
arrange for other broker-dealers to participate in resales.
In connection with distribution of the shares of Common Stock offered
hereby or otherwise, the Selling StockholdersHolders.
The Holders may enter into hedging transactions with broker-dealers.broker-dealers or
other financial institutions. In connection with such transactions,
broker-dealers or other financial institutions may engage in short sales of sharesthe
Registrable Securities or of Common Stock registered
hereundersecurities convertible into or exchangeable for the
Registrable Securities in the course of hedging the positions they assume with
the Selling
Stockholders.Holders. The Selling Stockholders may also sell shares of Common Stock
short and redeliver the shares of Common Stock registered hereunder to close out
such short positions. The Selling StockholdersHolders may also enter into optionoptions or other transactions with
broker-dealers or other financial institutions which require the delivery to
thesuch broker-dealers or other financial institutions of Registrable Securities
offered by this Prospectus, which Registrable Securities such broker-dealer of the shares of Common Stock registered hereunder, which the
broker dealeror
other financial institution may resell or otherwise transfer pursuant to this Prospectus.Prospectus (as amended
or supplemented to reflect such transaction).
The Selling Stockholder may also loan or pledge the shares of Common Stock
registered hereunder to a broker-dealer and the broker-dealer may sell the
shares of Common Stock so loaned or upon default the broker-dealerHolders may effect sales of the pledged shares pursuantsuch transactions by selling Registrable
Securities directly to this Prospectus. The Selling
Stockholderspurchasers or to or through broker-dealers, which may also pledge shares of Common Stock registered hereunder to a
lender other than a broker-dealer, and upon default such lender may sell the
shares of Common Stock so pledged pursuant to this Prospectus. The Selling
Stockholders may also contributeact
as agents or sell shares of Common Stock offered
hereunder to trusts or other entities for the benefit of the contributing
Selling Stockholder and members of his or her family.
Broker-dealers or agentsprincipals. Such broker-dealers may receive compensation in the
form of discounts, concessions or commissions discounts from Holders and/or concessions from the Selling Stockholderspurchasers
of Registrable Securities for whom such broker-dealers may act as agents or to
whom they sell as principal, or both (which compensation as to a particular
broker-dealer might be in amounts
to be negotiatedexcess of customary commissions).
The Holders and any broker-dealers that act in connection with the sale
of Common Stock. Such
broker-dealers and any other participating broker-dealers mayRegistrable Securities might be deemed to be "underwriters" within the
meaning of Section 2(11) of the Securities Act, in connection with such
sales and any commissions received by
such commission, discount or concession maybroker-dealers and any profit on the resale of the Registrable Securities
sold by them while acting as principals might be deemed to be underwriting
discounts or commissions under the Securities Act. In addition, any
securities covered by the Prospectus which qualify for sale under Rule 144 under
the Securities Act may be sold pursuantThe Company has agreed to
Rule 144 rather than pursuant to this
Prospectus.
-7--4-
11
All costs, expenses and fees in connection with the registration of the
shares of Common Stock offered hereby shall be borne by the Company. Commissions
and discounts, if any, attributable to the sales of shares of Common Stock
hereunder will be borne by the Selling Stockholders. The Selling Stockholders
may agree to8
indemnify any broker-dealer or agent that participates in a
transaction involving sales of shares of Common Stockeach Holder against certain liabilities, including liabilities arising
under the Securities Act. The Company
has agreedHolders may agree to indemnify any agent, dealer
or broker-dealer that participates in transactions involving sales of the
Selling StockholdersRegistrable Securities against certain liabilities, in
connection with the offering of the shares of Common Stock hereunder, including liabilities
arising under the Securities Act.
The Holders may be deemed to be "underwriters" within the meaning of
Section 2(11) of the Securities Act.
The Holders will be subject to the prospectus delivery requirements of
the Securities Act. The Company has informed the Holders that the
anti-manipulative provisions of Regulation M promulgated under the Exchange Act
may apply to their sales in the market.
Holders also may resell all or a portion of the Registrable Securities
in open market transactions in reliance upon Rule 144 under the Securities Act,
provided they meet the criteria and conform to the requirements of such Rule.
Upon the Company being notified by a Holder that any material
arrangement has been entered into with a broker-dealer for the sale of
Registrable Securities through a block trade, special offering, exchange
distribution or secondary distribution or a purchase by a broker or dealer, a
supplement to this Prospectus will be filed, if required, pursuant to Rule
424(b) under the Securities Act, disclosing (i) the name of each such Holder and
of the participating broker-dealer(s), (ii) the number of Registrable Securities
involved, (iii) the initial price at which such Registrable Securities were
sold, (iv) the commissions paid or discounts or concessions allowed to such
broker-dealer(s), where applicable, (v) that such broker-dealer(s) did not
conduct any investigation to verify the information set out or incorporated by
referenced in this Prospectus and (vi) other facts material to the transactions.
In addition, upon the Company being notified by a Holder that a donee or pledgee
intends to sell more than 500 Registrable Securities, a supplement to this
Prospectus will be filed.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The following documents filed with the Commission by the Company are
incorporated by reference in this Prospectus:
(1) the Company's Annual Report on Form 10-K for the year
ended December 31, 1998, as amended;1999;
(2) the Company's Quarterly Report on Form 10-Q for the three month
periods ended March 31, 1999.
(3) the Company's Current Report on Form 8-K filed on May 28, 1999;
and
(4) the description of the Company's Common Stock contained in
the Company's Registration Statement on form 8-A filed August 1, 1997,
including any amendment or report filed for the purposes of updating
such description.
All reports and other documents filed by the Company pursuant to
Sections 13(a), 14 or 15(d) of the Exchange Act after the date of this
Prospectus and prior to the termination of the offering of the Common Stock
shall be deemed to be incorporated by reference in this
-5-
9
Prospectus and to be part hereof from the date of filing of such documents. Any
statement contained herein or in a document incorporated or deemed to be
incorporated by reference herein shall be modified or superseded for purposes of
this Prospectus to the extent that a statement contained herein or in any other
subsequently filed document which also is or is deemed to be incorporated by
reference herein, modifies or supersedes such statement. Any statement so
modified or superseded shall not be deemed, except as so modified or superseded,
to constitute a part of this Prospectus.
A copy of the documents incorporated by reference (other than exhibits
thereto) will be forwarded without charge to each person to whom this Prospectus
is delivered, upon such person's written or oral request to International
Isotopes Inc., Office of the Secretary, 3100 Jim Christal1500 Spencer Road, Denton, Texas 76207-9987,76201,
telephone number (940) 484-9492.323-2610. The Company's internet address is
ilmorgan@intiso.com.
-8-
12dcamp@intiso.com.
LEGAL MATTERS
The validity of the shares of Common Stock offered hereby have been
passed upon for the Company by Locke Liddell & Sapp LLP, Austin, Texas.
EXPERTS
The consolidated financial statements of the Company as of December 31,
1997, and 1998 and 1999 and for the years then ended and theapplicable periods from November 1, 1995
(inception)inception to December 31,
1996 and December 31, 19981999 have been incorporated by reference herein in reliance on the report of
KPMG LLP, independent certified public accountants, incorporated by reference
herein and upon the authority of said firm as experts in auditing and
accounting.
AVAILABLE INFORMATION
The Company is subject to the informational requirements of the
Securities Exchange Act of 1934 (the "Exchange Act") and accordingly files
reports and other information with the Securities and Exchange Commission (the
"Commission"). Reports, proxy statements and other information filed by the
Company with the Commission can be inspected and copied, at prescribed rates, at
the Public Reference Room maintained by the Commission at 450 Fifth Street,
N.W., Washington, DC 20549. The public may obtain information on the operation
of the Public Reference Room by calling the Commission at 1-800-SEC-0330. The
Commission maintains an Internet web site at http://www.sec.gov/ that also
contains such reports, proxy statements and other information.
-6-
10
The Company has filed with the Commission a Registration Statement on
Form S-3 (including all amendments thereto, the "Registration Statement") under
the Securities Act of 1933, as amended (the "Securities Act"), with respect to
the Common Stock offered hereby. The Registration Statement has been filed
electronically with the Commission pursuant to its Electronic Data Gathering and
Retrieval ("EDGAR") system. As permitted by the rules and regulations of the
Commission, this Prospectus does not contain all the information set forth in
the Registration Statement.
-9--7-
1311
PART II
Information Not Required in Prospectus
ITEM 13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.
The estimated expenses of this offering, all of which will be paid by
Registrant, are as follows:
SEC Registration Fee $ 9,821.08
Boston Stock Exchange2,881.00
Nasdaq Listing Fee and BSE Listing Fee $ 5,500.00
Nasdaq Listing Fee $11,000.0012,773.00
Accounting Fees and Expenses $ 5,000.002,500.00
Registrant's Legal Fees and Expenses $20,000.00$ 5,000.00
Total $51,321.08$ 23,154.00
ITEM 14. INDEMNIFICATION OF DIRECTORS AND OFFICERS
As permitted by the Texas Business Corporation Act ("TBCA"), the
Company's Restated Articles of Incorporation provide that the Company will
indemnify its officers, directors, employees and agents to the fullest extent
permitted by the TBCA against actions that may arise against them in such
capacities, and advance expenses in connection with any such actions.
Registrant's Restated Articles of Incorporation provide that directors of the
Company will not be personally liable to Registrant or its stockholders for
monetary damages for any act or omission in his capacity as a director except as
authorized under the TBCA. The TBCA provides that a corporation may indemnify a
person who was, is, or is threatened to be made a named defendant in a
proceeding because such person is or was a director if it is determined in
accordance with the provisions of the TBCA that the person (i) conducted himself
in good faith, (ii) reasonably believed, in the case of conduct in his official
capacity as director, that his conduct was in the corporation's best interests
or, in other cases, that his conduct at least was not opposed to the
corporation's interests and (iii) in the case of any criminal proceeding, had no
reasonable cause to believe his conduct was unlawful. A director may not be
indemnified with respect to a proceeding in which the person is found liable on
the basis that personal benefit was improperly received by him, whether or not
the benefit resulted from an action taken in the person's official capacity, or
in which the person is found liable to the corporation. Officers, employees and
agents of a corporation are entitled to be indemnified by the corporation as,
and to the same extent provided for, directors of the corporation.
Registrant carries directors' and officers' liability insurance with an
aggregate policy limit of $5,000,000.
II-1
1412
ITEM 16. EXHIBITS.
Exhibits
4.1 Specimen Common Stock Certificate (incorporated by reference to Exhibit
4.1 to the Company's Registration Statement on Form SB-2 (Registration
No. 333-26269)).
4.2 Form of Warrant issued to investors in the Company's 1999 Private
Placement.
4.3 Amended and Restated Warrant Agreement entered into between the Company and
each of the investors in the Company's 1998 Private Placement (incorporated
by reference to Exhibit 5.1 to the Company's Form 8-K filed on May 28,
1999).
5.Selling Stockholders.
5 Opinion of Locke Liddell & Sapp LLP with respect to the legality of the
securities being registered hereby.
23.1*23.1 Consent of KPMG LLP
23.2 Consent of Locke Liddell & Sapp LLP (included in Exhibit 5).
24 Power of Attorney (included as part of Signature page).
* To be filed by Amendment
ITEM 17. UNDERTAKINGS.
Insofar as indemnification for liabilities arising under Securities Act
may be permitted to directors, officers and controlling persons of Registrant
pursuant to the provisions of its Restated Articles of Incorporation, its
By-Laws, the Texas Business Corporation Act or otherwise, Registrant has been
advised that in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the Securities Act and
is, therefore, unenforceable. In the event that a claim for indemnification
against liabilities (other than the payment by Registrant for expenses incurred
or paid by an officer, director or controlling person of Registrant in the
successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being
registered, Registrant will, unless in the opinion of its counsel the matter has
been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public
policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue.
(a) The undersigned Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are
being made, a post-effective amendment to this registration statement:
(i) To include any prospectus required by Section
10(a)(3) of the Securities Act;
(ii) To reflect in the prospectus any facts or events
arising after the effective date of the registration statement (or the most
recent post-effective amendment thereof) which, individually or in the
aggregate, represent a fundamental change in the information set II-2
15
forth in the
registration statement; and
II-2
13
(iii) To include any material information with
respect to the plan of distribution not previously disclosed in the registration
statement or any material change to such information in the registration
statement;
Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not
apply if the information required to be included in a post-effective amendment
by those paragraphs is contained in periodic reports filed by the Registrant
pursuant to Section 13 or Section 15(d) of the Exchange Act that are
incorporated by reference in the Registration Statement.
(2) That, for the purpose of determining any liability under
the Securities Act, each such post-effective amendment shall be deemed to be a
new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof.
(3) To remove from registration by means of a post-effective
amendment any of the securities being registered which remain unsold at the
termination of the offering.
(4) For purposes of determining any liability under the
Securities Act, the information omitted from the form of prospectus filed as
part of this registration statement in reliance upon Rule 430A and contained in
a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (40
or 497(b) under the Securities Act shall be deemed to be part of this
Registration Statement as of the time it was declared effective.
(b) The undersigned Registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act, each filing of the
registrant's annual report pursuant to Section 13(a) or Section 15(d) of the
Exchange Act that is incorporated by reference in the registration statement
shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be
deemed to be the initial bona fide offering thereof.
II-3
1614
POWER OF ATTORNEY TO SIGN AMENDMENTS
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature
appears below does hereby constitute and appoint IRA LON MORGANDAVID M. CAMP and CARL W. SEIDEL,JOAN H.
GILLETT, and each of them, with full power to act without the other, his true
and lawful attorney-in-fact and agent for him and in his name, place and stead,
in any and all capacities, to sign any or all amendments to this Registration
Statement and to file the same, with all exhibits thereto, and other documents
in connection therewith, with the Securities and Exchange Commission, granting
unto said attorneys-in-fact and agents, and each of them, full power and
authority to do and perform each and every act and thing requisite and necessary
to be done in and about the premises in order to effectuate the same, as fully,
for all intents and purposes, as he might or could do in person, hereby
ratifying and confirming all that said attorneys-in-fact and agents, or any of
them, may lawfully do or cause to be done by virtue hereof.
SIGNATURES
In accordance with the requirements of the Securities Act of 1933,
Registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-3 and authorized this Registration
Statement to be signed on its behalf by the undersigned, in the City of Denton,
State of Texas, on the 8th1 day of July, 1999.March, 2000.
INTERNATIONAL ISOTOPES INC.
By: /s/ Ira Lon Morgan.
---------------------------------------
Ira Lon Morgan, Ph.D.
Chairman of the Board and Treasurer
By: /s/ Carl W. Seidel.
---------------------------------------
Carl W. SeidelDavid M. Camp.
--------------------------
David M. Camp, President,
Chief Executive
OfficerCEO and Director
II-4
1715
In accordance with the requirements of the Securities Act of 1933, this
Registration Statement has been signed by the following persons in the
capacities and on the dates stated.
SIGNATURE TITLE DATE
--------- ----- ----
/s/ Carl W. SeidelDavid M. Camp President, Chief Executive July 8, 1999March 1, 2000
- -------------------------------------------------------------- Officer, and Director (Principal
Carl W. SeidelDavid M. Camp Executive Officer)
/s/ Joan H. Gillett Chief Financial Officer July 8, 1999March 1, 2000
- -------------------------------------------------------------- (Principal Financial and
Joan H. Gillett Accounting Officer)
/s/ Ira Lon Morgan Chairman of the Board and July 8, 1999
- ------------------------------ Treasurer
Ira Lon Morgan, Ph.D.
/s/ Tommy L. Thompson Executive Vice President, Chief July 8, 1999March 1, 2000
- -------------------------------------------------------------- Operating Officer and Director
Tommy L. Thompson
/s/ Virgil L. Simmons Senior Vice President March 1, 2000
- -------------------------------- and Director July 8, 1999
- ------------------------------
Virgil L. Simmons
/s/ Ira Lon Morgan Director March 1, 2000
- --------------------------------
Ira Lon Morgan, Ph.D.
/s/ John M. McCormack Director July 8, 1999March 1, 2000
- --------------------------------------------------------------
John M. McCormack
/s/ William W. Nicholson Director July 8, 1999Chairman of the March 1, 2000
- -------------------------------------------------------------- Board of Directors
William W. Nicholson
/s/ Robert J. Gary Director July 8, 1999March 1, 2000
- --------------------------------------------------------------
Robert J. Gary
/s/ Frederick J. Bonte Director July 8, 1999March 1, 2000
- --------------------------------------------------------------
Frederick J. Bonte, M.D.
/s/ Charles LeMaistre Director July 8, 1999March 1, 2000
- --------------------------------------------------------------
Charles LeMaistre, M.D.
Director March 1, 2000
- --------------------------------
Carl W. Seidel
II-5
1816
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
- ------------------ -----------
4.1 Specimen Common Stock Certificate (incorporated by reference to Exhibit
4.1 to the Company's Registration Statement on Form SB-2 (Registration
No. 333-26269)).
4.2 Form of Warrant issued to investors in the Company's 1999 Private
Placement.
4.3 Amended and Restated Warrant Agreement entered into between the Company
and each of the investors in the Company's 1998 Private Placement
(incorporated by reference to Exhibit 5.1 to the Company's Form 8-K
filed on May 28, 1999).
5.Selling Stockholders.
5 Opinion of Locke Liddell & Sapp LLP with respect to the legality of the
securities being registered hereby.
23.1*23.1 Consent of KPMG LLP
23.2 Consent of Locke Liddell & Sapp LLP (included in Exhibit 5).
24 Power of Attorney (included as part of Signature page).
* To be filed by Amendment